Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 482, Issue 3, Pages 459-469Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2016.10.100
Keywords
BCL-2; Apoptosis; Cancer; BH3-Mimetics; ABT-199; Venetoclax
Categories
Funding
- Leukemia Foundation of Australia
- National Health and Medical Research Council [1020363, 1016701, 10460101, 1059290, 1078924]
- Cancer Council Victoria [1052309]
- Leukemia and Lymphoma Society [7001-13]
- Australian Government IRISS
- Victorian State Government [OIS 9000220]
- National Health and Medical Research Council of Australia [1078924, 1059290] Funding Source: NHMRC
Ask authors/readers for more resources
In 1988, the BCL-2 protein was found to promote cancer by limiting cell death rather than enhancing proliferation. This discovery set the wheels in motion for an almost 30 year journey involving many international research teams that has recently culminated in the approval for a drug, ABT-199/venetoclax/Venclexta that targets this protein in the treatment of cancer. This review will describe the long and winding path from the discovery of this protein and understanding the fundamental process of apoptosis that BCL-2 and its numerous homologues control, through to its exploitation as a drug target that is set to have significant benefit for cancer patients. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available